Thiotepa in the Treatment of Advanced Breast Cancer
1965

Thiotepa for Advanced Breast Cancer

Sample size: 72 publication Evidence: low

Author Information

Author(s): A. R. Lyons, G. A. Edelstyn

Primary Institution: Northern Ireland Radiotherapy Centre

Hypothesis

Can thiotepa effectively treat advanced breast cancer?

Conclusion

Thiotepa treatment resulted in a low remission rate and significant risks, making it less favorable compared to other treatments.

Supporting Evidence

  • Only 32% of patients had an objective remission.
  • The mean duration of response was 8 months.
  • Patients with bony metastases had a better chance of response.
  • Mortality rate from treatment was 11%.
  • High doses of thiotepa showed better response rates.

Takeaway

Thiotepa is a medicine used for breast cancer, but it doesn't work very well and can be dangerous.

Methodology

Patients with advanced breast cancer were treated with thiotepa and testosterone, and their responses were monitored.

Potential Biases

Potential bias due to previous hormone treatments affecting outcomes.

Limitations

The study could not reproduce previous high remission rates and had a significant mortality rate.

Participant Demographics

Patients with progressive metastasizing breast cancer, most having prior hormone therapy.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.01

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication